Table 4.

rAAV tools which can be applied to studies of neurodegenerative proteinopathies in BSCs

rAAV Tool	Promoter(s)	Capsid(s)	Experimental model	Reference(s)
Non-Specific global gene expression	hybrid cytomegalovirus enhancer/chicken β-actin (hCBA)	2/1, 2/2, 2/6, 2/8, 2/9	BSCs	[29]
Microglial expression	CD68	2/6 with three mutations Y731F/Y705F/T492 V (TM6)	BSCs	[29]
Neuronal expression	CamKII or MAP-2	2/6, 2/8	BSCs	[29]
Oligodendrocyte expression	MBP	2/8	BSCs	[29]
Astrocyte expression	GFAP	2/8	BSCs	[29]
Calcium-Sensing e.g. GCaMP6 or REX-GECO1	Synapsin, chicken β-actin (CAG) or cytomegalovirus (CMV)	2/1	In vivo rodent, BSCs	[95, 96]
Voltage-Sensing e.g. Archon1 or Voltron	CamKII or CAG	–	Acute BSCs, Primary Hippocampal Neurons	[94]
Retrograde Tracing	CMV or Synapsin	2-retro (Mutant r5H6 (insert LADQDYTKTA + V708I + N382D))	In vivo rodent	[98]
Optogenetics e.g. Channelrhodopsin-2	CAG	2/1	In vivo rodent, Acute BSCs	[99]
Chemogenetics e.g. DREADDs	Synapsin	2/8	In vivo rodent, Acute BSCs	[97]
Recombination e.g. Cre	CMV	2/2	In vivo rodent	[100]
Gene Editing e.g. CRISPR/Cas9	CMV	DJ, 2/9	In vivo rodent	[92]
Gene Silencing e.g. shRNA	Modified CMV, H1	2/1	In vivo rodent	[93]